Crescent Biopharma, Inc. (CBIO): who owns it and who trades it
As of Nov 16, 2026, CBIO insiders reported 16 open-market sales worth $1.5M and 2 purchases worth $30.6M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Joshua T Brumm (CEO), with $921K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Crescent Biopharma
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CBIO
80 funds and institutions reported CBIO shares worth $525M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 4.13M | 14.99% | $74.4M | No change |
| Bvf Inc | 2.75M | 9.97% | $49.5M | No change |
| Fairmount Funds Management LLC | 2.75M | 9.97% | $49.5M | No change |
| Venrock Adviser, LLC | 2.13M | 7.74% | $38.4M | No change |
| Logos Global Management LP | 1.90M | 6.89% | $34.2M | +294% |
| Fcpm III Services B.v. | 1.68M | 6.09% | $30.2M | No change |
| Balyasny Asset Management L.P. | 1.66M | 6.03% | $29.9M | +10% |
| Vestal Point Capital, LP | 1.63M | 5.91% | $29.3M | +9% |
| Opaleye Management Inc. | 1.32M | 4.79% | $23.7M | +1% |
| BlackRock, Inc. | 1.27M | 4.61% | $22.9M | +999% |
| Tang Capital Management LLC | 1.16M | 4.21% | $20.9M | No change |
| Vanguard Capital Management LLC | 767,755 | 2.78% | $13.8M | -4% |
| Millennium Management LLC | 403,859 | 1.46% | $7.3M | +25% |
| Geode Capital Management, LLC | 384,576 | 1.39% | $6.9M | +269% |
| Jennison Associates LLC | 378,507 | 1.37% | $6.8M | +147% |
| NEXTBio Capital Management LP | 372,856 | 1.35% | $6.7M | No change |
| Rtw Investments, LP | 372,856 | 1.35% | $6.7M | No change |
| Remedium Capital Partners, LLC | 361,250 | 1.31% | $6.5M | New |
| State Street Corp | 315,587 | 1.14% | $5.7M | +708% |
| Ameriprise Financial Inc | 302,568 | 1.10% | $5.4M | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CBIO insiders reported $30.6M of open-market purchases and $1.5M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Joshua T Brumm | CEO | Sale plan | 7,837 | $16.71 | $131K | Form 4 |
| Sep 18, 2026 | Jonathan McNeill | President | Sale plan | 3,839 | $16.71 | $64.1K | Form 4 |
| Sep 16, 2026 | Ryan Lynch | See Remarks | Sale plan | 240 | $17.90 | $4.3K | Form 4 |
| Sep 16, 2026 | Jan Pinkas | Chief Scientific Officer | Sale plan | 658 | $17.90 | $11.8K | Form 4 |
| Sep 16, 2026 | Ellie Eunkyung Im | Chief Medical Officer | Sale plan | 623 | $17.90 | $11.2K | Form 4 |
| Sep 16, 2026 | Richard William Scalzo | CFO | Sale plan | 568 | $17.90 | $10.2K | Form 4 |
| Sep 16, 2026 | Barbara Harlin Bispham | See Remarks | Sale plan | 620 | $17.90 | $11.1K | Form 4 |
| Sep 16, 2026 | Joshua T Brumm | CEO | Sale plan | 1,610 | $17.90 | $28.8K | Form 4 |
| Sep 16, 2026 | Jonathan McNeill | President | Sale plan | 731 | $17.90 | $13.1K | Form 4 |
| Jul 16, 2026 | Fairmount Healthcare Fund II L.P. +3 | Director | Purchase | 853,450 | $14.50 | $12.4M | Form 4 |
| Jun 22, 2026 | Ryan Lynch | See Remarks | Sale plan | 465 | $17.99 | $8.4K | Form 4 |
| Jun 22, 2026 | Jan Pinkas | Chief Scientific Officer | Sale plan | 1,288 | $17.99 | $23.2K | Form 4 |
| Jun 22, 2026 | Richard William Scalzo | CFO | Sale plan | 1,112 | $17.99 | $20K | Form 4 |
| Jun 22, 2026 | Barbara Harlin Bispham | See Remarks | Sale plan | 1,218 | $17.99 | $21.9K | Form 4 |
| Jun 22, 2026 | Ellie Eunkyung Im | Chief Medical Officer | Sale plan | 1,219 | $17.99 | $21.9K | Form 4 |
| Jun 22, 2026 | Jonathan McNeill | President | Sale plan | 20,549 | $17.99 | $370K | Form 4 |
| Jun 22, 2026 | Joshua T Brumm | CEO | Sale plan | 42,305 | $17.99 | $761K | Form 4 |
| Dec 4, 2025 | Peter Evan Harwin +3 | Director | Purchase | 1.36M | $13.41 | $18.2M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Peter Evan Harwin | Director, 10% owner | $18.2M | – | Dec 4, 2025 |
| Fairmount Healthcare Fund II L.P. | Director, 10% owner | $12.4M | – | Jul 16, 2026 |
| Joshua T Brumm | Chief Executive Officer, Director | – | $921K | Sep 18, 2026 |
| Jonathan McNeill | President and COO | – | $447K | Sep 18, 2026 |
| Jan Pinkas | Chief Scientific Officer | – | $34.9K | Sep 16, 2026 |
| Ellie Eunkyung Im | Chief Medical Officer | – | $33.1K | Sep 16, 2026 |
| Barbara Harlin Bispham | See Remarks | – | $33K | Sep 16, 2026 |
| Richard William Scalzo | Chief Financial Officer | – | $30.2K | Sep 16, 2026 |
| Ryan Lynch | See Remarks | – | $12.7K | Sep 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CBIO short interest
High short interest. 11.2% of CBIO shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 43%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.16M CBIO shares were sold short, 11.2% of the shares outstanding, down 5.8% from the report before. At the average daily volume of 255,474 shares, buying them all back would take about 16.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.16M | 11.20% | -6% | 255,474 | 16.3 |
| Oct 15, 2026 | 4.42M | 11.90% | -7% | 349,105 | 12.7 |
| Sep 30, 2026 | 4.78M | 12.86% | +40% | 697,402 | 6.8 |
| Sep 15, 2026 | 3.41M | 9.17% | +7% | 400,407 | 8.5 |
| Aug 31, 2026 | 3.17M | 8.54% | -1% | 159,313 | 19.9 |
| Aug 14, 2026 | 3.22M | 8.66% | -7% | 187,795 | 17.1 |
| Jul 31, 2026 | 3.47M | 9.33% | -7% | 388,342 | 8.9 |
| Jul 15, 2026 | 3.74M | 13.58% | +2% | 384,904 | 9.7 |
| Jun 30, 2026 | 3.67M | 13.32% | +10% | 522,826 | 7.0 |
| Jun 15, 2026 | 3.35M | 12.14% | +3% | 212,363 | 15.8 |
| May 29, 2026 | 3.26M | 11.81% | +12% | 289,116 | 11.3 |
| May 15, 2026 | 2.90M | 10.52% | +21% | 344,475 | 8.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Crescent Biopharma company events
Crescent Biopharma filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 15, 2026.
- Oct 15, 2026AnnouncementCrescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens in its global Phase 1/2 ASCEND trial, (ii) the initiation of additional… Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jul 15, 2026AnnouncementCrescent Biopharma, Inc. entered into an underwriting agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of (i) 8,094,793 of the Company’s ordinary shares, par value US$0.001… Filing
- Jul 14, 2026ResultsReleased financial results. Filing
- Jun 3, 2026VoteReported shareholder vote results. Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Dec 4, 2025AgreementCrescent Biopharma Operating Company, LLC, the wholly owned subsidiary of Crescent Biopharma, Inc., a Cayman Islands exempted company (together with its subsidiaries, “Crescent” or the “Company”), entered into two license agreements with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., each of… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Crescent Biopharma financials
Famous investors that hold CBIO
3 of the 50 well-known investors we track reported holding CBIO in their latest 13F filing. The largest position is Ken Griffin's, worth $5.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 349,656 | $5.1M | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 84,896 | $1.2M | 0.0% | -79% |
| George Soros · Soros Fund Management | Q3 2026 | 20,000 | $292K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named CBIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 4.3% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 5.2% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 8.1% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 5.2% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 4.3% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 5.9% |
| Nov 16, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 5.9% |
| Nov 16, 2026 | Vestal Point Capital, LP | 13G/A | 8.1% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.6% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.6% |
Questions about Crescent Biopharma, Inc. (CBIO) stock
Who owns the most CBIO stock?
The largest reported owner of Crescent Biopharma, Inc. (CBIO) is FMR LLC (Fidelity), with 15.0% of the company. In total, 80 funds and institutions reported holding CBIO at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CBIO insiders buying or selling?
In the last 12 months, CBIO insiders reported 2 open-market purchases worth $30.6M and 16 sales worth $1.5M. The latest trade was on Sep 18, 2026. See every trade.
What is the short interest in CBIO?
As of Oct 30, 2026, 4.16M CBIO shares were sold short, 11.2% of the shares outstanding, down 5.8% from the report before. At the average daily volume of 255,474 shares, buying them all back would take about 16.3 trading days (days to cover). See the history.
Which famous investors hold CBIO?
3 of the 50 well-known investors we track reported CBIO in their latest 13F filing, including Ken Griffin, Israel Englander, George Soros. The largest position is worth $5.1M. See all holders.
Executive pay
Crescent Biopharma's chief executive was paid a total of $13.1M for the year ended Dec 31, 2025. In the last 12 months, Crescent Biopharma's executives and directors bought $18.2M of stock on the open market and sold $1.5M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.